Moreover, further analysis of SPTBN1 for predicting ICI therapy response in patients with KIRC revealed that SPTBN1 was potentially involved in the resistance of certain ICI therapy, such as CTLA-4 blocker and CTLA-4 plus PD1 blockers in KIRC(revised_Figure 11); meanwhile, further study of SPTBN1 for predicting anti-cancer targeted therapy response in individuals with UVM demonstrated that SPTBN1 might also have a potential to involve in the enhance of anti-cancer targeted treatment in UVM (revised_Figure 12). This evidence concerns the gene PDCD1 and cancer.